Switzerland Ranks 3rd Globally in R&D Intensity

Switzerland continues to strengthen its position as a global innovation hub, with major companies ranking among the world’s top investors in research and development (R&D), according to a new EY study published on Tuesday.

The analysis of the world’s 500 largest corporate R&D spenders shows that Swiss firms achieved the third-highest research intensity globally in 2025, measured by the ratio of R&D spending to revenue. Only companies in the United States and the Netherlands ranked higher.

Swiss corporations recorded an average R&D intensity of 8.4%, significantly above the European average of 6.7%, although still below the United States, which leads with 9.2%.

In total, Swiss companies invested approximately €34 billion (CHF 31.2 billion) in innovation last year, placing Switzerland sixth worldwide in total R&D expenditure.

The study highlights the strong contribution of Basel-based pharmaceutical giants. Roche remains one of the world’s leading investors in innovation, spending €14.3 billion on R&D. Novartis also plays a key role, investing €9.9 billion and ranking among the top global companies.

According to EY analysts, medicines continue to be the most research-intensive industry worldwide, reflecting the importance of pharmaceutical innovation in Switzerland’s economy.

However, the report also highlights a growing gap between Europe and the United States. While American companies increased R&D spending by 12% in 2025, European firms saw only a 5% increase, with relatively stagnant revenue growth.

At the global level, technology giants dominate absolute R&D spending. Companies such as Amazon, Alphabet (Google), and Meta (Facebook) lead the rankings, with Amazon alone investing more than €96 billion, largely driven by artificial intelligence development.

EY concludes that global companies are prioritising innovation more than ever, with R&D budgets growing faster than overall revenues. This trend reinforces the importance of research investment in maintaining long-term competitiveness.

Roche Acquires AI Specialist PathAI in Major Healthcare Deal.

Swiss pharmaceutical giant Roche has announced the acquisition of American artificial intelligence company PathAI as part of its strategy to strengthen AI-powered healthcare and digital pathology solutions.

The deal is valued at $750 million, with additional milestone payments that could increase the total value by up to $300 million.

Through the acquisition, Roche aims to expand its leadership in AI-based diagnostic technologies and accelerate the development of personalized medicine.

PathAI specializes in artificial intelligence systems used in pathology and medical diagnostics. Its AI-powered Image Management System (IMS) helps laboratories improve efficiency, analyze medical images faster, and support clinical decision-making.

Roche stated that combining PathAI’s technology with Roche’s diagnostic expertise will help speed up the development of new therapies, improve laboratory operations, and support the discovery of new biomarkers and advanced diagnostic tools.

The two companies already began collaborating in 2021, with the partnership expanding further in 2024 before the acquisition announcement.

Roche expects the transaction to be finalized during the second half of 2026, pending approval from regulatory and competition authorities.

After completion, PathAI will be integrated into Roche’s diagnostics division, strengthening the company’s position in the growing field of AI-driven healthcare innovation.

The move highlights the increasing importance of artificial intelligence in global healthcare, where pharmaceutical companies are investing heavily in digital diagnostics, precision medicine, and automated laboratory technologies.